Pharmaniaga Berhad Statistics

Total Valuation

KLSE:PHARMA has a market cap or net worth of MYR 360.31 million. The enterprise value is 1.43 billion.

Market Cap	360.31M
Enterprise Value	1.43B

Important Dates

The next estimated earnings date is Monday, May 19, 2025.

Earnings Date	May 19, 2025
Ex-Dividend Date	n/a

Share Statistics

KLSE:PHARMA has 1.44 billion shares outstanding. The number of shares has increased by 5.38% in one year.

Current Share Class	n/a
Shares Outstanding	1.44B
Shares Change (YoY)	+5.38%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	4.19%
Owned by Institutions (%)	10.93%
Float	488.58M

Valuation Ratios

The trailing PE ratio is 2.73 and the forward PE ratio is 7.35.

PE Ratio	2.73
Forward PE	7.35
PS Ratio	0.10
PB Ratio	-2.47
P/TBV Ratio	n/a
P/FCF Ratio	31.31
P/OCF Ratio	8.44
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 4.80, with an EV/FCF ratio of 123.86.

EV / Earnings	10.81
EV / Sales	0.38
EV / EBITDA	4.80
EV / EBIT	5.46
EV / FCF	123.86

Financial Position

The company has a current ratio of 0.62

Current Ratio	0.62
Quick Ratio	0.30
Debt / Equity	n/a
Debt / EBITDA	4.01
Debt / FCF	103.57
Interest Coverage	3.63

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	8.35%
Return on Invested Capital (ROIC)	16.61%
Return on Capital Employed (ROCE)	665.07%
Revenue Per Employee	1.08M
Profits Per Employee	37,923
Employee Count	3,476
Asset Turnover	1.92
Inventory Turnover	5.39

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.90% in the last 52 weeks. The beta is 1.35, so KLSE:PHARMA's price volatility has been higher than the market average.

Beta (5Y)	1.35
52-Week Price Change	-20.90%
50-Day Moving Average	0.24
200-Day Moving Average	0.34
Relative Strength Index (RSI)	52.85
Average Volume (20 Days)	1,589,790

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KLSE:PHARMA had revenue of MYR 3.76 billion and earned 131.82 million in profits. Earnings per share was 0.09.

Revenue	3.76B
Gross Profit	540.49M
Operating Income	260.93M
Pretax Income	194.18M
Net Income	131.82M
EBITDA	297.24M
EBIT	260.93M
Earnings Per Share (EPS)	0.09

Full Income Statement

Balance Sheet

The company has 152.20 million in cash and 1.19 billion in debt, giving a net cash position of -1.04 billion or -0.72 per share.

Cash & Cash Equivalents	152.20M
Total Debt	1.19B
Net Cash	-1.04B
Net Cash Per Share	-0.72
Equity (Book Value)	-145.94M
Book Value Per Share	-0.12
Working Capital	-748.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 42.67 million and capital expenditures -31.16 million, giving a free cash flow of 11.51 million.

Operating Cash Flow	42.67M
Capital Expenditures	-31.16M
Free Cash Flow	11.51M
FCF Per Share	0.01

Full Cash Flow Statement

Margins

Gross margin is 14.38%, with operating and profit margins of 6.94% and 3.51%.

Gross Margin	14.38%
Operating Margin	6.94%
Pretax Margin	5.17%
Profit Margin	3.51%
EBITDA Margin	7.91%
EBIT Margin	6.94%
FCF Margin	0.31%

Dividends & Yields

KLSE:PHARMA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-5.38%
Shareholder Yield	-5.38%
Earnings Yield	36.59%
FCF Yield	3.19%

Dividend Details

Stock Splits

The last stock split was on July 5, 2021. It was a forward split with a ratio of 5.

Last Split Date	Jul 5, 2021
Split Type	Forward
Split Ratio	5

Scores

KLSE:PHARMA has an Altman Z-Score of 1.69. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.69
Piotroski F-Score	n/a